Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsRoland J. Fuchs, Katharina Kohlbrenner, Frank Stegelmann et al.|Leukemia|2017Cited by 339